Moderna's dual flu and Covid-19 vaccine shows promising results in advanced trials

Moderna, a pharmaceutical company, announces that its dual flu and COVID-19 vaccine, designed to address both diseases with a single injection, has successfully completed a crucial phase of advanced scientific evaluations.

Moderna has developed the mRNA-1083

Moderna has developed the mRNA-1083, which will aid in protecting people from these serious illnesses. A test was conducted for this vaccine, involving over 8,000 participants aged 50 and above. Half of them received the combined vaccine, while the rest were administered separate vaccines for COVID-19 and flu.

When compared, the group receiving the combination vaccine produced 20% to 40% more antibodies against influenza strains and 30% more antibodies against COVID-19 variants. It is hoped that this vaccine will be available in the market by 2026.

Effective Against Most Influenza Strains

Research has indicated that the combined vaccine may have a longer shelf life. Additionally, mRNA technology has been used for the influenza component. This vaccine could be highly effective against most strains of influenza. It has shown effectiveness against both Influenza A group strains and Influenza B strains.

Prof John Tregoning, an immunologist at Imperial College London, said work on a dual vaccine was "a promising direction of travel", but that the science world awaited the full data for scrutiny.

Moderna is also developing an mRNA vaccine against a disease called cytomegalovirus, for which it hopes to have late-stage trial results this autumn.

Also watch: Teenager's lung punctures after vaping for weeks, know how harmful e cigarettes can be